Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1986 1
1990 1
1991 1
1994 1
1999 1
2001 3
2002 2
2003 2
2004 2
2005 1
2006 4
2007 3
2008 3
2009 4
2010 5
2011 4
2012 1
2013 10
2014 10
2015 14
2016 15
2017 9
2018 11
2019 9
2020 17
2021 27
2022 31
2023 27
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following terms were ignored: %, %, %, %
The following terms were not found in PubMed: 22Chrousos, 5BAuthor
Page 1
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, Bouchard M, Budur K, Carroll C, Chaudhuri KR, Criswell SR, Danielsen EH, Gandor F, Jia J, Kimber TE, Mochizuki H, Robieson WZ, Spiegel AM, Standaert DG, Talapala S, Facheris MF, Fung VSC. Aldred J, et al. Neurol Ther. 2023 Dec;12(6):1937-1958. doi: 10.1007/s40120-023-00533-1. Epub 2023 Aug 26. Neurol Ther. 2023. PMID: 37632656 Free PMC article.
Secondary endpoints included changes from baseline in normalized "Off" and "On" time, percentage of patients reporting morning akinesia, Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Parkinson's Disease Sleep Scale-2 (PDSS-2), 39-item Parkinson's …
Secondary endpoints included changes from baseline in normalized "Off" and "On" time, percentage of patients reporting morning akinesia, Mov …
Mapping the FACT-G to EQ-5D-3L utility index in cancer with the Chinese values set.
He Z, Liang W, Xu W, Huang W, Wang X, Huang K, Yang L. He Z, et al. Expert Rev Pharmacoecon Outcomes Res. 2022 Oct;22(7):1103-1116. doi: 10.1080/14737167.2022.2091546. Epub 2022 Jun 21. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 35711123
METHOD: A cross-sectional study among 243 Chinese patients with cancer was conducted through EQ-5D-3 L and FACT-G questionnaires survey. The EQ-5D-3 L utility index values were predicted based on OLS, GLM, CLAD, and Tobit model regression approaches. ...CONCL …
METHOD: A cross-sectional study among 243 Chinese patients with cancer was conducted through EQ-5D-3 L and FACT-G questionnair …
Tiotropium / Olodaterol -- Addendum to Commission A15-31 [Internet].
Institute for Quality and Efficiency in Health Care. Institute for Quality and Efficiency in Health Care. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2016 Jan 14. Extract of Dossier Assessment No. A15-57. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2016 Jan 14. Extract of Dossier Assessment No. A15-57. PMID: 29144706 Free Books & Documents. Review.
Background On 22 December 2015, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct supplementary assessments for Commission A15-31 (Tiotropium / Olodaterol - Benefit Assessment According to 35a …
Background On 22 December 2015, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in He …
Biologics for chronic rhinosinusitis.
Chong LY, Piromchai P, Sharp S, Snidvongs K, Philpott C, Hopkins C, Burton MJ. Chong LY, et al. Cochrane Database Syst Rev. 2020 Feb 27;2(2):CD013513. doi: 10.1002/14651858.CD013513.pub2. Cochrane Database Syst Rev. 2020. PMID: 32102112 Free PMC article. Updated.
At 24 weeks, the SNOT-22 score was 19.61 points lower (better) in participants receiving dupilumab (mean difference (MD) -19.61, 95% confidence interval (CI) -22.54 to -16.69; 3 studies; 784 participants; high certainty). ...Anti-IL-5 mAb (mepolizumab) versusplacebo …
At 24 weeks, the SNOT-22 score was 19.61 points lower (better) in participants receiving dupilumab (mean difference (MD) -19.61, 95% …
Comparison of the three-level and the five-level versions of the EQ-5D.
Christiansen ASJ, Møller MLS, Kronborg C, Haugan KJ, Køber L, Højberg S, Brandes A, Graff C, Diederichsen SZ, Nielsen JB, Krieger D, Holst AG, Svendsen JH. Christiansen ASJ, et al. Eur J Health Econ. 2021 Jun;22(4):621-628. doi: 10.1007/s10198-021-01279-z. Epub 2021 Mar 18. Eur J Health Econ. 2021. PMID: 33733344
A total of 1002 persons diagnosed with hypertension, diabetes, heart failure, and/or previous stroke completed both the EQ-5D-3L and the EQ-5D-5L questionnaires. The overall ceiling effect decreased from 46% with the EQ-5D-3L to 30% with the EQ-5D-5L a …
A total of 1002 persons diagnosed with hypertension, diabetes, heart failure, and/or previous stroke completed both the EQ-5D-3L and …
Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer.
Criscitiello C, Spurden D, Piercy J, Rider A, Williams R, Mitra D, Wild R, Corsaro M, Kurosky SK, Law EH. Criscitiello C, et al. Clin Ther. 2021 Jul;43(7):1228-1244.e4. doi: 10.1016/j.clinthera.2021.04.020. Epub 2021 Jul 11. Clin Ther. 2021. PMID: 34256965
Descriptive summary statistics were reported for FACT-B, Functional Assessment of Cancer Therapy-General (FACT-G) (total and specific subscales), the EQ-5D index scores, and the EQ-VAS scores for each country. ...In addition, mean scores were comparable between the …
Descriptive summary statistics were reported for FACT-B, Functional Assessment of Cancer Therapy-General (FACT-G) (total and specific …
Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study.
Hümmert MW, Bütow F, Tkachenko D, Ayzenberg I, Pakeerathan T, Hellwig K, Klotz L, Häußler V, Stellmann JP, Warnke C, Goereci Y, Etgen T, Luessi F, Bronzlik P, Gingele S, Lauenstein AS, Kleiter I, Rommer PS, Paul F, Bellmann-Strobl J, Duchow A, Then Bergh F, Pul R, Walter A, Pellkofer H, Kümpfel T, Pompsch M, Kraemer M, Albrecht P, Aktas O, Ringelstein M, Senel M, Giglhuber K, Berthele A, Jarius S, Wildemann B, Trebst C; Neuromyelitis Optica Study Group (NEMOS). Hümmert MW, et al. Neurol Neuroimmunol Neuroinflamm. 2023 Jan 24;10(2):e200082. doi: 10.1212/NXI.0000000000200082. Print 2023 Mar. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 36693760 Free PMC article.
Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clinical characteristics were retrieved from the NEMOS database. ...The reported HRQoL did not decline compared with a prepandemic assessment (m …
Health-related quality of life (HRQoL) was measured with the EuroQoL Group 5-Dimension 5-Level Scale (EQ-5D-5L). Demographic and clin …
Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs.
Ghabri S, Lam L, Bocquet F, Spath HM. Ghabri S, et al. Pharmacoeconomics. 2020 May;38(5):459-471. doi: 10.1007/s40273-020-00887-6. Pharmacoeconomics. 2020. PMID: 32052376 Review.
Individual models such as discrete-event simulations were used in over two-fifths (22/51, 43%) of the selected studies. Few studies (7/51, 14%) used utility scores based on generic instruments (e.g. EQ-5D). Estimation of hospitalization costs was described in …
Individual models such as discrete-event simulations were used in over two-fifths (22/51, 43%) of the selected studies. Few studies ( …
Corticosteroid implants for chronic non-infectious uveitis.
Reddy A, Liu SH, Brady CJ, Sieving PC, Palestine AG. Reddy A, et al. Cochrane Database Syst Rev. 2023 Jan 16;1(1):CD010469. doi: 10.1002/14651858.CD010469.pub3. Cochrane Database Syst Rev. 2023. PMID: 36645716 Free PMC article. Updated. Review.
Findings Using sham procedure as control, combined results at the six-month primary time point suggested that corticosteroid implants may decrease the risk of uveitis recurrence by 60% (relative risk [RR] 0.40, 95% confidence interval [CI] 0.30 to 0.54; 2 trials, 282 participants …
Findings Using sham procedure as control, combined results at the six-month primary time point suggested that corticosteroid implants may de …
A systematic review of patient-reported outcome measures for advanced skin cancer patients.
Reinhardt ME, Sun T, Pan CX, Schmults CD, Lee EH, Waldman AB. Reinhardt ME, et al. Arch Dermatol Res. 2023 Aug;315(6):1473-1480. doi: 10.1007/s00403-022-02479-0. Epub 2022 Dec 5. Arch Dermatol Res. 2023. PMID: 36469125 Review.
A total of 1,998 articles were identified. 82 met our inclusion criteria resulting in 22 PROMs: five generic health-related (QWB-SA, AQoL-8D, EQ-5D, SF-36, and PRISM), six general cancer (EORTC QLQ-C30, EORTC QLQ-C36, LASA, IOC, Rotterdam Symptom Checklist, and FACT …
A total of 1,998 articles were identified. 82 met our inclusion criteria resulting in 22 PROMs: five generic health-related (QWB-SA, …
196 results